Cell
Volume 112, Issue 6, 21 March 2003, Pages 845-857
Journal home page for Cell

Article
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl

https://doi.org/10.1016/S0092-8674(03)00191-0Get rights and content
Under an Elsevier user license
open archive

Abstract

The c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption of these mechanisms in the Bcr-Abl oncoprotein leads to several forms of human leukemia. We found that like Src kinases, c-Abl 1b is activated by phosphotyrosine ligands. Ligand-activated c-Abl is particularly sensitive to the anti-cancer drug STI-571/Gleevec/imatinib (STI-571). The SH2 domain-phosphorylated tail interaction in Src kinases is functionally replaced in c-Abl by an intramolecular engagement of the N-terminal myristoyl modification with the kinase domain. Functional studies coupled with structural analysis define a myristoyl/phosphotyrosine switch in c-Abl that regulates docking and accessibility of the SH2 domain. This mechanism offers an explanation for the observed cellular activation of c-Abl by tyrosine-phosphorylated proteins, the intracellular mobility of c-Abl, and it provides new insights into the mechanism of action of STI-571.

Cited by (0)

5

These authors contributed equally to this work.

6

Present address: Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, WC2A 3PX London, United Kingdom.